MEDICAL POLICY DETAILS

<table>
<thead>
<tr>
<th>Medical Policy Title</th>
<th>BRACHYTHERAPY OR RADIOACTIVE SEED IMPLANTATION FOR PROSTATE CANCER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy Number</td>
<td>6.01.16</td>
</tr>
<tr>
<td>Category</td>
<td>Technology Assessment</td>
</tr>
<tr>
<td>Effective Date</td>
<td>10/18/01</td>
</tr>
<tr>
<td>Revised Date</td>
<td>10/18/01, 05/16/02, 06/19/03, 05/19/04, 05/18/05, 05/18/06, 04/19/07, 04/17/08, 04/16/09, 05/27/10, 06/16/11, 06/21/12, 06/20/13, 06/19/14, 07/16/15, 07/21/16, 08/17/17, 10/18/18, 11/21/19</td>
</tr>
</tbody>
</table>
| Product Disclaimer   | • If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply.  
• If a commercial product (including an Essential Plan product) or a Medicaid product covers a specific service, medical policy criteria apply to the benefit.  
• If a Medicare product covers a specific service, and there is no national or local Medicare coverage decision for the service, medical policy criteria apply to the benefit. |

POLICY STATEMENT

I. Based upon our criteria and assessment of peer-reviewed literature, permanent brachytherapy or high dose rate brachytherapy for prostate cancer is medically appropriate for the following indications:
   A. Permanent brachytherapy or high dose rate brachytherapy as monotherapy for the following indications:
      1. patient diagnosed with clinically organ-confined disease, and
      2. prostate cancer classified stage less than T3a, and
      3. Gleason score less than 8, or
      4. PSA level less than 20 ng/mL.
   B. Permanent brachytherapy or high dose rate brachytherapy in conjunction with EBRT for the following indications:
      1. patient diagnosed with clinically localized disease, and
      2. prostate cancer classified stage T2b, T2c, T3a, T4, and
      3. Gleason score greater than or equal to 7 but less than or equal to 10, or
      4. PSA level greater than 10 ng/mL.

II. Based upon our criteria and assessment of the peer reviewed literature, high dose rate temporary brachytherapy as monotherapy has not been proven to be effective and is therefore investigational for high-risk prostate cancer.

Refer to Corporate Medical Policy #7.01.01 regarding Cryosurgery for Prostate Cancer.

POLICY GUIDELINES

The Federal Employee Health Benefit Program (FEHBP/FEP) requires that procedures, devices or laboratory tests approved by the U.S. Food and Drug Administration (FDA) may not be considered investigational and thus these procedures, devices or laboratory tests may be assessed only on the basis of their medical necessity.

DESCRIPTION

Brachytherapy is the term used to describe radioactive seeds placed inside the body to deliver radiation near the site of the malignancy. Brachytherapy may be thought of as internal radiation in contrast to external beam radiation in which radiation is directed through the body area from an outside source. Seed implant treatment for prostate cancer refers to the placement of tiny radioactive pellets, or seeds, directly into the prostate using needles guided by radiological imaging, usually, but not exclusively, ultrasound. Rows of seeds are deposited uniformly throughout the prostate so that the radiation can cover the entire gland. There are 2 major methods of prostate brachytherapy, permanent seed implantation and high dose rate (HDR) temporary brachytherapy.
In permanent brachytherapy, the radioactive seeds are implanted interstitially, using the transperineal route with the guidance of transrectal ultrasound, fluoroscopy (sometimes) and/or computed tomography. The seeds release radiation at a low dose rate gradually over a period of time (6 to 12 months) after which they become inert. The most common seeds used in permanent brachytherapy are Iodine 125 and Palladium 103. The seeds do not have to be removed and can remain in the prostate for the rest of the patient’s life. The American Brachytherapy Society recommends that postoperative dosimetry be performed on each patient who has undergone permanent radioactive seed implantation. Without this information it is impossible to confirm the actual dose delivered or to identify any variance from the treatment plan.

In contrast, HDR temporary brachytherapy involves placing tiny plastic catheters into the prostate gland and then delivering multiple radiation treatments (fractions) through these catheters with a high energy radioisotope such as iridium 192. The radioactive source is “afterloaded” or temporarily inserted into the prostate for a calculated duration at various “dwell positions” (usually 8-12 minutes). HDR brachytherapy can be fractionated or delivered in several sessions per day or over a course of several days. Radiation treatment planning and computerized dose calculations are needed to determine the prostate and tumor dose distribution and to control the radiation dose to the adjacent normal tissues such as rectum, bladder, and urethra. HDR brachytherapy permits precise delivery of radiation at a high rate to the prostate and immediate surrounding areas. In addition to efficacy in the low and intermediate grade prostate cancers, it is believed to be more effective in destroying rapidly dividing cancer cells, as seen in poorly differentiated malignancies.

Hormone therapy may be considered as a neo-adjuvant therapy to permanent seed implantation, HDR brachytherapy, or external beam radiation therapy to selectively reduce prostate size and induce tumor regression.

RATIONAL

Brachytherapy as a procedure does not require FDA approval. Radioactive isotopes of iodine-125, palladium-103 and iridium-192 have been cleared for marketing via 510(k).

Peer-reviewed literature demonstrates that permanent brachytherapy using the transperineal approach provides excellent control of the disease in low stage and low to moderate grade tumors, similar to those with 3D conformal EBRT or radical prostatectomy. For patients with intermediate risk disease, 3D conformal EBRT with or without brachytherapy, or radical prostatectomy provided comparable long-term disease-free survival. The transperineal approach offers minimal morbidity in appropriately selected patients, generally results in minimal impairment of the patient’s lifestyle, can be performed in an outpatient setting or with a short hospital stay of one or two days.

Considering the widespread increase in the use of permanent and high dose rate brachytherapy as a treatment option, evidence is sufficient to permit conclusions on its safety and efficacy in a select patient population. There is no data to support that high dose rate brachytherapy monotherapy is superior to other existing modalities as a lone treatment option for prostate cancer.

CODES

- Eligibility for reimbursement is based upon the benefits set forth in the member’s subscriber contract.
- CODES MAY NOT BE COVERED UNDER ALL CIRCUMSTANCES. PLEASE READ THE POLICY AND GUIDELINES STATEMENTS CAREFULLY.
- Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently than policy updates.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>55875</td>
<td>Transperineal placement of needles or catheters into prostate for interstitial radioelement application, with or without cystoscopy</td>
</tr>
<tr>
<td>55876</td>
<td>Placement of interstitial device(s) for radiation therapy guidance (e.g. fiducial markers, dosimeter), prostate (via needle, any approach), single or multiple</td>
</tr>
<tr>
<td>76965</td>
<td>Ultrasonic guidance for interstitial radioelement application</td>
</tr>
<tr>
<td>77014</td>
<td>Computed tomography guidance for placement of radiation therapy fields</td>
</tr>
</tbody>
</table>
**HCPCS Codes**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C1716</td>
<td>Brachytherapy source, nonstranded, gold 198, per source</td>
</tr>
<tr>
<td>C1719</td>
<td>Brachytherapy source, nonstranded, non-high dose rate iridium 192, per source</td>
</tr>
<tr>
<td>C2637</td>
<td>Brachytherapy source, nonstranded, ytterbium-169, per source</td>
</tr>
<tr>
<td>C2638</td>
<td>Brachytherapy source, stranded, iodine-125, per source</td>
</tr>
<tr>
<td>C2639</td>
<td>Brachytherapy source, nonstranded, iodine-125, per source</td>
</tr>
</tbody>
</table>

*Proprietary Information of Univera Healthcare*
Medical Policy: BRACHYTHERAPY OR RADIOACTIVE SEED IMPLANTATION FOR PROSTATE CANCER
Policy Number: 6.01.16
Page: 4 of 6

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C2640</td>
<td>Brachytherapy source, stranded, palladium-103, per source</td>
</tr>
<tr>
<td>C2641</td>
<td>Brachytherapy source, nonstranded, palladium-103, per source</td>
</tr>
<tr>
<td>C2645</td>
<td>Brachytherapy planar source, palladium-103, per square millimeter</td>
</tr>
<tr>
<td>G0458</td>
<td>Low dose rate (LDR) prostate brachytherapy services, composite rate</td>
</tr>
<tr>
<td>Q3001</td>
<td>Radioelements for brachytherapy, any type, each</td>
</tr>
<tr>
<td></td>
<td>The following codes may be E/I if used alone.</td>
</tr>
<tr>
<td>C1717</td>
<td>Brachytherapy source, nonstranded, high dose rate iridium-192, per source</td>
</tr>
<tr>
<td>C9725</td>
<td>Placement of endorectal intracavity applicator for high intensity brachytherapy</td>
</tr>
</tbody>
</table>

ICD10 Codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C61</td>
<td>Malignant neoplasm of prostate</td>
</tr>
<tr>
<td>D07.5</td>
<td>Carcinoma in situ of prostate</td>
</tr>
</tbody>
</table>

REFERENCES


*Key Article

KEY WORDS
High-dose rate brachytherapy, Low-dose rate brachytherapy, Permanent brachytherapy, Prostate brachytherapy, Temporary brachytherapy.

CMS COVERAGE FOR MEDICARE PRODUCT MEMBERS
There is currently no National Coverage Determination (NCD) or Local Coverage Determination (LCD) for Brachytherapy.